All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
9 warning events since 2022; the latest 2026-05-15.
From the record
ASP Isotopes Inc.'s filings since 2022 show 9 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, the latest 2023-05-10); a late-report notice (Form NT 10-K or NT 10-Q, 8 times, the latest 2026-05-15) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
4 filed years; profitable in 0 of 4.
From the record
ASP Isotopes Inc.'s 4 filed years say what it did: it rose in 2 of 2 years; it never fell from a peak; net income was positive in 0 of 4 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 0.6/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: ASP Isotopes Inc.'s shareholder treatment is put at 0.6 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 6% of 9 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -78%: lost 78¢ per shareholder dollar. Leverage 59%: owes 59¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, ASP Isotopes Inc. lost about 78 cents for every dollar of shareholders' money, and gross profitability: its products earned about 1 cents per dollar of everything the company owns. Leverage: it owed about 59 cents per dollar of assets, and net share issuance: its share count grew 49.1% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 11% of 9 in its family; net margin -670.2%.
From the record
ASP Isotopes Inc.'s standing among 9 graded names in its industry family: revenue of $24 million in fiscal 2025 ranks in the bottom 6% by size; a net margin of -670.2% ranks in the bottom 17% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
bottom 7% of 7 in its family for leadership; chief executive since 2026.
From the record
ASP Isotopes Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Mann, Paul Elliot (Chairman and CEO, as filed), filing under that title since 2026-06-03, 5 months (bottom 6% of its family); the 9 officers and directors filing in the last fifteen months have been on the record a median of 3.1 years (bottom 7%); 9 officer or director changes were reported on Form 8-K since 2023-11-13, against the 9 people in charge now (bottom 7%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
top 50% of 8 in its family for room to expand.
From the record
ASP Isotopes Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $286 million against debt of $14 million leaves 54.5% of its assets as net cash, top 6% of its family; cash from operations less capital spending is -198.9% of revenue (bottom 6%); a gross margin of 14.3% (bottom 6%); research spending of 51.8% of revenue (top 6%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 9% of 9 in its family for growth drivers.
From the record
ASP Isotopes Inc.'s growth drivers, from the filed years to fiscal 2025: the newest year grew 476.2% (top 6%); research spending grew 113.3% a year (top 6%); capital spending grew 29.2% a year (top 17%) (its annual reports). ASP Isotopes Inc. reported 2 product lines in fiscal 2025: Construction at $18 million (76%), Product at $6 million (24%); 1 of 1 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 47% of 8 in its family for expectations against reality.
From the record
ASP Isotopes Inc.'s newest year against its own record: net income of $160 million against a prior three-year average of $18 million (bottom 13%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 6%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made